Skip to main content
SpringerLink
Log in

Ivabradine may increase cardiovascular risk

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. EudraCT2009-011360-10 (Clinical Trials Insight profile 700048079)

References

  1. MHRA. Ivabradine: emerging clinical trial evidence of increased cardiovascular risk - carefully monitor for bradycardia. Drug Safety Update 7: S1, No. 11, Jun 2014. Available from: URL: http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con428334.pdf.

    Google Scholar 

  2. TGA - Therapeutic Goods Administration. Ivabradine (Coralan) and cardiovascular events in patients with angina. Internet Document : 23 Jun 2014. Available from: URL: http://www.tga.gov.au/safety/ews-medicine-ivabradine-140623.htm.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ivabradine may increase cardiovascular risk. Reactions Weekly 1508, 3 (2014). https://doi.org/10.1007/s40278-014-1639-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-1639-2

Search

Navigation